With more than 250 votes cast, Jennifer Doudna is leading by a decisive margin in a poll
asking who deserves the patent for use of CRISPR-Cas9 as a tool.
Feng Zhang got only just over half the votes of Doudna.
Another take home message from this poll is that a sizable minority–almost one in five– said neither should have a patent on this technology.
Geographically the results were fairly consistent across countries, but notably in the UK the top response was, “Neither”.
This poll is of course non-scientific, but it is interesting even so to see a fairly decisive result.
Let’s see ultimately what happens with the US Patent Office.
Here’s an update from 2020 on the CRISPR patent battle. How can it still be going on?